Arya Gupta

Arya Gupta

Auto-generated profile, based on publicly available information

Arya Gupta

Biomedical Science, School of Health, Leeds Beckett University, Leeds, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CRChristopher P. Randall
Christopher P. Randall
AGArya Gupta
Arya Gupta
NJNicole Jackson
Nicole Jackson
DBDavid Busse
David Busse
AOAlex J. O'Neill
Alex J. O'Neill
To gain a more detailed understanding of endogenous (mutational) and exogenous (horizontally acquired) resistance to silver in Gram-negative pathogens, with an emphasis on clarifying the genetic bases for resistance. A suite of microbiological and molecular genetic techniques was employed to select and characterize endogenous and exogenous silver resistance in several Gram-negative species. In Escherichia coli, endogenous resistance arose after 6 days of exposure to silver, a consequence of two point mutations that were both necessary and sufficient for the phenotype. These mutations, in ompR and cusS, respectively conferred loss of the OmpC/F porins and derepression of the CusCFBA efflux transporter, both phenotypic changes previously linked to reduced intracellular accumulation of silver. Exogenous resistance involved derepression of the SilCFBA efflux transporter as a consequence of mutation in silS, but was additionally contingent on expression of the periplasmic silver-sequestration protein SilE. Silver resistance could be selected at high frequency (>10−9) from Enterobacteriaceae lacking OmpC/F porins or harbouring the sil operon and both endogenous and exogenous resistance were associated with modest fitness costs in vitro. Both endogenous and exogenous silver resistance are dependent on the derepressed expression of closely related efflux transporters and are therefore mechanistically similar phenotypes. The ease with which silver resistance can become selected in some bacterial pathogens in vitro suggests that there would be benefit in improved surveillance for silver-resistant isolates in the clinic, along with greater control over use of silver-containing products, in order to best preserve the clinical utility of silver.

26 December 2018 in mSphere
Verified
Journal Article
Open access
CRChristopher P. Randall
Christopher P. Randall
AGArya Gupta
Arya Gupta
BUBret Utley-Drew
Bret Utley-Drew
SLSiu Yi Lee
Siu Yi Lee
GMGenevieve Morrison-Williams
Genevieve Morrison-Williams
AOAlex J. O’neill
Alex J. O’neill
NIS and related bacteriocins are of interest as candidates for the treatment of human infections caused by Gram-positive pathogens such as Staphylococcus aureus . An important liability of NIS in this regard is the ease with which S. aureus acquires resistance. Here we establish that this organism naturally possesses the cellular machinery to detoxify NIS but that the ABC transporter responsible (VraDE) is not ordinarily produced to a degree sufficient to yield substantial resistance. Acquired NIS resistance mutations prompt activation of the regulatory circuit controlling expression of vraDE , thereby unmasking an intrinsic resistance determinant. Our results provide new insights into the complex mechanism by which expression of vraDE is regulated and suggest that a potential route to overcoming the resistance liability of NIS could involve chemical modification of the molecule to prevent its recognition by the VraDE transporter.

26 April 2022 in mSystems
Verified
Journal Article
Open access
QLQuentin Leclerc
Quentin Leclerc
JWJacob Wildfire
Jacob Wildfire
AGArya Gupta
Arya Gupta
JLJodi Lindsay
Jodi Lindsay
GKGwenan Knight
Gwenan Knight
Bacteriophage (phage), viruses that can infect and kill bacteria, are being investigated through phage therapy as a potential solution to the threat of antimicrobial resistance (AMR). In reality, however, phage are also natural drivers of bacterial evolution by transduction when they accidentally carry nonphage DNA between bacteria.

23 January 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MCMichael H. Charlton
Michael H. Charlton
RARihards Aleksis
Rihards Aleksis
ASAdélaïde Saint-Leger
Adélaïde Saint-Leger
AGArya Gupta
Arya Gupta
ELEinars Loza
Einars Loza
PFPaul William Finn
Paul William Finn

23 October 2023 in Heliyon
Verified
Journal Article
Open access
SVStanislavs Vasiljevs
Stanislavs Vasiljevs
AGArya Gupta
Arya Gupta
DBDeborah L Baines
Deborah L Baines
People with cystic fibrosis-related diabetes (CFRD) suffer from chronic infections with Staphylococcus aureus and/or Pseudomonas aeruginosa. In people with CFRD, the concentration of glucose in the airway surface liquid (ASL) was shown to be elevated from 0.4 to 4 mM. The effect of glucose on bacterial growth/interactions in ASL is not well understood and here we studied the relationship between these lung pathogens in artificial sputum medium (ASM), an environment similar to ASL in vivo.

28 June 2022 in Letters in Applied Microbiology
Verified
Journal Article
Open access
AGA. Gupta
A. Gupta
LBL. Bernacchia
L. Bernacchia
NKN.M. Kad
N.M. Kad
Cisplatin was originally discovered through its antibacterial action and subsequently has found use as a potent broad-spectrum anticancer agent. This study determines the effect of growth media and solvent on the antibacterial activity of cisplatin and its analogue, oxaliplatin. Escherichia coli MG1655 or MG1655 ΔtolC was treated with the platinum compounds under different conditions and susceptibility was determined. Our results showed that DMSO reduced the activity of cisplatin by fourfold (MIC 12·5 mg l−1) compared with 0·9% NaCl-solubilized cisplatin (MIC 3·12 mg l−1) when tested in MOPS. Surprisingly, complete loss of activity was observed in Mueller–Hinton Broth II (MHB II). By supplementing MOPS with individual components of MHB II such as the sulphur-containing amino acids, l-cysteine and l-methionine, individually or in combination reduced activity by ≥8-fold (MIC ≥25 mg l−1). Oxaliplatin was less active against E. coli (MIC 100 mg l−1) but exhibited similar inactivation in the presence of DMSO, MHBII or MOPS spiked with l-cysteine and l-methionine (MIC ≥400 mg l−1). Our data suggest that the antibacterial activity of cisplatin and oxaliplatin is modulated by both choice of solvent and composition of growth media. We demonstrate that this is primarily due to sulphur-containing amino acids cysteine and methionine, an essential component of the recommended media for testing antimicrobial susceptibility, MHBII.